Prescription Drug News and Research RSS Feed - Prescription Drug News and Research

Common drug used for treating fungal infections in lung transplant recipients increases risk for skin cancer, death

Common drug used for treating fungal infections in lung transplant recipients increases risk for skin cancer, death

Voriconazole, a prescription drug commonly used to treat fungal infections in lung transplant recipients, significantly increases the risk for skin cancer and even death, according to a new study by UC San Francisco researchers. [More]
Report: 3 out of 4 U.S. adults have hearts older than their actual age

Report: 3 out of 4 U.S. adults have hearts older than their actual age

Your heart may be older than you are – and that's not good. According to a new CDC Vital Signs report, 3 out of 4 U.S. adults have a predicted heart age that is older than their actual age. This means they are at higher risk for heart attacks and stroke. [More]
Tocagen's Toca 511 & Toca FC receives FDA orphan drug designation for treatment of glioblastoma

Tocagen's Toca 511 & Toca FC receives FDA orphan drug designation for treatment of glioblastoma

Tocagen Inc., a clinical-stage immuno-oncology company, today announced that the U.S. Food and Drug Administration has granted orphan drug designation to the company's lead immuno-oncology product candidate, Toca 511 & Toca FC, for the treatment of glioblastoma. [More]
AMA Task Force to Reduce Opioid Abuse announces national recommendations to address opioid crisis

AMA Task Force to Reduce Opioid Abuse announces national recommendations to address opioid crisis

Opioid abuse is a serious public health problem that has reached crisis levels across the United States, with 44 people dying each day from overdose of opioids, and many more becoming addicted. Recognizing the urgency and serious impact of this issue on the health of hundreds of thousands of patients across the country, today the American Medical Association Task Force to Reduce Opioid Abuse announced the first of several national recommendations to address this growing epidemic. [More]
FDA accepts Allergan's resubmission of BOTOX sBLA for treatment of adults with upper limb spasticity

FDA accepts Allergan's resubmission of BOTOX sBLA for treatment of adults with upper limb spasticity

Allergan plc, a leading global pharmaceutical company today announced that the U.S. Food and Drug Administration has accepted the company's resubmission of its Supplemental Biologics License Application (sBLA) for BOTOX (onabotulinumtoxinA) for the treatment of adults with lower limb (involving ankle and toe muscles) spasticity in adults. [More]
Growing availability of heroin changing the face of opiate addiction in the U.S.

Growing availability of heroin changing the face of opiate addiction in the U.S.

The growing availability of heroin, combined with programs aimed at curbing prescription painkiller abuse, may be changing the face of opiate addiction in the U.S., according to sociologists. [More]
FDA accepts Chiasma's NDA filing for octreotide capsules for treatment of adult patients with acromegaly

FDA accepts Chiasma's NDA filing for octreotide capsules for treatment of adult patients with acromegaly

Chiasma, Inc., a U.S. late-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration has accepted for filing the Company's New Drug Application (NDA) for the marketing and sale of octreotide capsules, an oral drug proposed for the maintenance therapy of adult patients with acromegaly. [More]
New study examines how race and gender relate to Medicare Part D's coverage gap

New study examines how race and gender relate to Medicare Part D's coverage gap

Medicare Part D provides help to beneficiaries struggling with the cost of prescriptions drugs, but the plan's coverage gap hits some populations harder than others, particularly African-Americans age 65 and older. Reaching, or even approaching, the gap affects access to medication and influences whether those medications are taken as prescribed. [More]
Envarsus XR granted FDA orphan drug designation for prophylaxis of organ rejection in kidney transplant patients

Envarsus XR granted FDA orphan drug designation for prophylaxis of organ rejection in kidney transplant patients

Veloxis Pharmaceuticals A/S, today announced that Envarsus XR was granted Orphan Drug status by the U.S. Food and Drug Administration for prophylaxis of organ rejection in patients who convert from immediate-release tacrolimus. Envarsus XR received marketing authorization from the FDA on July 10, 2015. [More]
Meridian Health Plan has second highest rate of HPV vaccinations in U.S. for female adolescents

Meridian Health Plan has second highest rate of HPV vaccinations in U.S. for female adolescents

Meridian Health Plan of Illinois has the second highest rate of human papillomavirus (HPV) vaccinations for female adolescents among all health plans in the country reporting HEDIS data to the National Committee for Quality Assurance. [More]
ADDF establishes Goodes Prize to recognize scientists in Alzheimer's drug discovery research

ADDF establishes Goodes Prize to recognize scientists in Alzheimer's drug discovery research

Thanks to the generosity of former Warner-Lambert CEO and Chairman Melvin R. Goodes and his family, the Alzheimer's Drug Discovery Foundation has established the only prize specifically recognizing scientists in Alzheimer's drug discovery research. Mr. Goodes—who has been open about his own Alzheimer's diagnosis—is an honorary member of the ADDF's Board of Governors. [More]
BMC partners with RIH, CVS to support pharmacy-based naloxone rescue kits to help combat opioid addiction, overdose

BMC partners with RIH, CVS to support pharmacy-based naloxone rescue kits to help combat opioid addiction, overdose

Boston Medical Center has received a $1.3 million grant from the Agency for Healthcare Research and Quality to support a demonstration project of pharmacy-based naloxone rescue kits to help reduce opioid addiction and overdose death in two New England States: Massachusetts and Rhode Island. [More]
Benefits and risks of taking antidepressant medications during pregnancy

Benefits and risks of taking antidepressant medications during pregnancy

Treating maternal psychiatric disorder with commonly used antidepressants is associated with a lower risk of certain pregnancy complications including preterm birth and delivery by Caesarean section, according to researchers at Columbia University's Mailman School of Public Health, Columbia University Medical Center, and the New York State Psychiatric Institute. However, the medications -- selective serotonin reuptake inhibitors, or SSRIs -- resulted in an increased risk of neonatal problems. [More]
People with chronic insomnia may be able to get relief from half of standard sleeping pills

People with chronic insomnia may be able to get relief from half of standard sleeping pills

The roughly nine million Americans who rely on prescription sleeping pills to treat chronic insomnia may be able to get relief from as little as half of the drugs, and may even be helped by taking placebos in the treatment plan, according to new research published today in the journal Sleep Medicine by researchers from the Perelman School of Medicine at the University of Pennsylvania. [More]
Antimicrobial coating for portable communication devices developed by Lucideon and King’s

Antimicrobial coating for portable communication devices developed by Lucideon and King’s

International materials technology specialist Lucideon has developed a new infection control method to tackle problems associated with digital technology in hospitals. [More]

Compliance - Hear from CCO from Lundbeck, Daiichi Sankyo and Novartis

With tightening transparency requirements the pharmaceutical industry is under increasing pressure to ensure fully compliant communication and interactions through all areas of their business functions. How can you evolve current business practices to build a real cross functional, promotional compliance organisation? [More]

DigiPharm- Meet the who’s who in digital and multichannel marketing

Marketing is not working well enough to serve the needs of the industry or the changing expectations of the patient. It is time to analyse what we are doing well, and where we need to invest effort and embrace genuine customer engagement. It’s time to embrace innovative technologies, improve standard practice and roll out more valuable technologies when justified and create truly integrated, inspiring multichannel engagement campaigns. [More]
Majority of Canadians support inclusion of private drug plans in pan-Canadian pharmacare program

Majority of Canadians support inclusion of private drug plans in pan-Canadian pharmacare program

While a strong majority of Canadians support the concept of a pan-Canadian pharmacare program, they don't necessarily want it to replace their existing private prescription drug plans according to a national survey conducted as part of the Canadian Pharmacists Association's Pharmacare 2.0 Initiative. [More]
Novogen's Anisina granted FDA Orphan Drug Designation for neuroblastoma

Novogen's Anisina granted FDA Orphan Drug Designation for neuroblastoma

US-Australian drug discovery company, Novogen Limited, today announced that it has received notification from the U.S. Food and Drug Administration that its chemotherapy candidate drug, Anisina, has been granted Orphan Drug Designation for neuroblastoma. [More]
National Safety Council requests employers to develop workplace policies around use of opioid painkillers

National Safety Council requests employers to develop workplace policies around use of opioid painkillers

The National Safety Council is calling on employers to develop workplace policies around the use of opioid prescription painkillers after reviewing research and court cases showing the negative impacts of these medicines on employee safety and worker's compensation costs. [More]
Advertisement